Clinical observation of levodopaand benserazide hydrochio-ride for treatment of restless legs syndrome with uremia
ZHAO Weidong?
CHEN Linfang
ZHANG Liqin
Abstract：Objective To observe the effect of madopar on uremia patients with restless legs syndrome ( RLS ) . Methods Forty-six patients with uremia and RLS were randomly divided into 2 groups: the treatment group with 23 cases, given madopar treatment;control group with 23 cases, given alprazolam;2, 4 weeks after treatment, the effect were observed by using the International Restless Legs Syndrome Study Group ( IRLSSG ) ’ s questionnaire score and the Pittsburgh sleep quality index ( PSQI) score. Results The 2 groups of patients after treatment, IRLSSG score were significantly decreased than before treatment, the treatment group from (22. 74 ± 7. 30) points decreased to (13. 04 ± 7. 06) points after 4 weeks of treatment, the control group from (20. 87 ± 7. 31) points down to (17. 74 ± 7. 28) points after 4 weeks of treatment, IRLSSG score of the treatment group were decreased more significantly than in the control group, the difference was statistically signifi-cant ( P <0. 05);the 2 groups of patients after treatment, PSQI score were significantly decreased than before treatment, the treatment group decreased from (16. 12 ± 4. 60) points to after 4 weeks’ (6. 19 ± 3. 21) points, the control group decreased from before treatment’s (16. 87 ± 4. 72) points to 4 weeks’ (9. 35 ± 4. 15) points, PSQI score of the treatment group were decreased more significantly than in the control group, the difference was statistically significant ( P <0. 05);no obvious ad-verse reaction were found in the 2 groups. Conclusion Madopar is safe and effective for treatment of uremia patients with restless legs syndrome.
Keywords：MadoparRestless legs syndrome with uremiaTherapeutic effect
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 148-150 )